Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00233038 · ClinicalTrials.gov registry record · Phase 2
EUS-Guided Pancreatic Injection of Cyst (EPIC) Trial
A Phase 2 study of Pancreatic Cystadenoma, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT00233038: Completed Phase 2 study of Pancreatic Cystadenoma, sponsored by Massachusetts General Hospital.
NCT00233038 is a Phase 2 study of Pancreatic Cystadenoma that has completed, run by Massachusetts General Hospital. The registered enrollment target is 50 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00233038, a Phase 2 study of Pancreatic Cystadenoma, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to learn about a new treatment for pancreatic cystic lesions. The injection of alcohol into cysts is a common way of treating cysts of the liver, kidney, and thyroid. We would like to find out if injection of alcohol would be useful for the treatment of pancreatic cystic lesions. The treatment with alcohol will use endoscopy and endoscopic ultrasound (procedures that use a scope that is placed through your mouth and into your stomach). We hypothesize that more than half of the cysts which are injected with ethanol will resolve.
Conditions Studied
Interventions
- PROCEDURE Ethanol injection into a cyst
Study Locations (1)
Indiana
- Indiana University Medical Center - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2005-01 |
| Est. Completion | 2008-03 |
| Phase | Phase 2 |
What the finished NCT00233038 record still lists
NCT00233038 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (62% lower).
The record links to 1 condition, with Pancreatic Cystadenoma appearing as the primary indexed condition, and to 1 intervention - of which Ethanol injection into a cyst is the first listed.
NCT00233038 reports a single indexed study location in Indiana.
Frequently Asked Questions
What is clinical trial NCT00233038 about?
NCT00233038 is a clinical study titled "EUS-Guided Pancreatic Injection of Cyst (EPIC) Trial". The purpose of the study is to learn about a new treatment for pancreatic cystic lesions. The injection of alcohol into cysts is a common way of treating cysts of the liver, kidney, and thyroid. We would like to find out if injection of alcohol would be useful for the treatment of pancreatic cystic ...
What is the current status of trial NCT00233038?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2005-01. Estimated completion is 2008-03.
What conditions does trial NCT00233038 study?
This clinical trial studies the following conditions: Pancreatic Cystadenoma.
What interventions are being tested in trial NCT00233038?
The interventions under investigation include: Ethanol injection into a cyst (PROCEDURE).
Who is sponsoring clinical trial NCT00233038?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00233038 being conducted?
This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00233038's enrollment target sits among peer trials
50 1195th of 2000 higher than 740 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia